PCI Biotech to present poster at the Second International Cancer Immunotherapy Conference
Oslo, September 23, 2016 – PCI Biotech will present a poster at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 2016. This year’s event is called “Translating Science into Survival” and is held at the Sheraton Times Square Hotel and the New York Hilton Midtown in New York City, September 25-28, 2016. The company will be represented by Dr. Tone Otterhaug, Clinical Science Director, and the poster will be available at the company’s website under News.
About the Second International Cancer Immunotherapy Conference:
The CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference is a jointly sponsored conference by the leaders in this field: the Cancer Research Institute (CRI), the Association for Cancer lmmunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR). This year’s program will focus on "Translating Science into Survival," and feature talks from more than 60 leaders in the field covering all areas of inquiry in cancer immunology and immunotherapy, including: antigens and vaccines, and emerging technologies.
About PCI Biotech:
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead fimaChem programme consists of a Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.For more information visit: www.pcibiotech.com
Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429